Separately, JPMorgan Chase & Co. set a $90.00 target price on shares of Duke Energy and gave the stock a hold rating in a report on Monday, May 20th.
Shares of IPSEN S A/S stock opened at $33.17 on Monday. The company has a market cap of $11.10 billion, a P/E ratio of 19.06, a P/E/G ratio of 1.22 and a beta of 0.49. The business has a fifty day moving average price of $32.12. IPSEN S A/S has a fifty-two week low of $27.58 and a fifty-two week high of $44.60.
Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity.
Featured Article: Investing strategies using the yield curve
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for IPSEN S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN S A/S and related companies with MarketBeat.com's FREE daily email newsletter.